» Articles » PMID: 33442016

Immune Determinants of COVID-19 Disease Presentation and Severity

Overview
Journal Nat Med
Date 2021 Jan 14
PMID 33442016
Citations 358
Authors
Affiliations
Soon will be listed here.
Abstract

COVID-19, caused by SARS-CoV-2 infection, is mild to moderate in the majority of previously healthy individuals, but can cause life-threatening disease or persistent debilitating symptoms in some cases. The most important determinant of disease severity is age, with individuals over 65 years having the greatest risk of requiring intensive care, and men are more susceptible than women. In contrast to other respiratory viral infections, young children seem to be less severely affected. It is now clear that mild to severe acute infection is not the only outcome of COVID-19, and long-lasting symptoms are also possible. In contrast to severe acute COVID-19, such 'long COVID' is seemingly more likely in women than in men. Also, postinfectious hyperinflammatory disease has been described as an additional outcome after SARS-CoV-2 infection. Here I discuss our current understanding of the immunological determinants of COVID-19 disease presentation and severity and relate this to known immune-system differences between young and old people and between men and women, and other factors associated with different disease presentations and severity.

Citing Articles

Post-COVID-19 Condition Prediction in Hospitalised Cancer Patients: A Machine Learning-Based Approach.

Mahvash Mohammadi S, Rumyantsev M, Abdeeva E, Baimukhambetova D, Bobkova P, El-Taravi Y Cancers (Basel). 2025; 17(4).

PMID: 40002280 PMC: 11853530. DOI: 10.3390/cancers17040687.


Analysis of differential expression of matrix metalloproteinases and defensins in the nasopharyngeal milieu of mild and severe COVID-19 cases.

Imtiaz K, Farooqui N, Ahmed K, Zhamalbekova A, Anwar M, Nasir A PLoS One. 2025; 20(2):e0304311.

PMID: 39965032 PMC: 11835293. DOI: 10.1371/journal.pone.0304311.


Characterizing temporal and global host innate immune responses against SARS-CoV-1 and -2 infection in pathologically relevant human lung epithelial cells.

Tat V, Drelich A, Huang P, Khanipov K, Hsu J, Widen S PLoS One. 2025; 20(1):e0317921.

PMID: 39874350 PMC: 11774383. DOI: 10.1371/journal.pone.0317921.


The complex landscape of immune dysregulation in multisystem inflammatory syndrome in children with COVID-19.

Guo J, Wang L Life Med. 2025; 3(4):lnae034.

PMID: 39872865 PMC: 11749780. DOI: 10.1093/lifemedi/lnae034.


homeRNA self-blood collection enables high-frequency temporal profiling of presymptomatic host immune kinetics to respiratory viral infection: a prospective cohort study.

Lim F, Lea H, Dostie A, Kim S, van Neel T, Hassan G EBioMedicine. 2025; 112:105531.

PMID: 39826256 PMC: 11786902. DOI: 10.1016/j.ebiom.2024.105531.


References
1.
van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B . Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020; 382(16):1564-1567. PMC: 7121658. DOI: 10.1056/NEJMc2004973. View

2.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

3.
Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

4.
Moghadas S, Fitzpatrick M, Sah P, Pandey A, Shoukat A, Singer B . The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A. 2020; 117(30):17513-17515. PMC: 7395516. DOI: 10.1073/pnas.2008373117. View

5.
Brodin P . Why is COVID-19 so mild in children?. Acta Paediatr. 2020; 109(6):1082-1083. DOI: 10.1111/apa.15271. View